A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To assess the safety, tolerability and plasma pharmacokinetics (PK) of SAR245408 given once
daily as a tablet formulation of polymorph E in subjects with solid tumors or lymphoma.